首页> 外文期刊>Journal of Ophthalmology >Current Treatment Limitations in Age-Related Macular Degeneration and Future Approaches Based on Cell Therapy and Tissue Engineering
【24h】

Current Treatment Limitations in Age-Related Macular Degeneration and Future Approaches Based on Cell Therapy and Tissue Engineering

机译:与年龄相关的黄斑变性的当前治疗局限性和基于细胞治疗和组织工程的未来方法

获取原文
           

摘要

Age-related macular degeneration (AMD) is the leading cause of blindness in the Western world. With an ageing population, it is anticipated that the number of AMD cases will increase dramatically, making a solution to this debilitating disease an urgent requirement for the socioeconomic future of the European Union and worldwide. The present paper reviews the limitations of the current therapies as well as the socioeconomic impact of the AMD. There is currently no cure available for AMD, and even palliative treatments are rare. Treatment options show several side effects, are of high cost, and only treat the consequence, not the cause of the pathology. For that reason, many options involving cell therapy mainly based on retinal and iris pigment epithelium cells as well as stem cells are being tested. Moreover, tissue engineering strategies to design and manufacture scaffolds to mimic Bruch’s membrane are very diverse and under investigation. Both alternative therapies are aimed to prevent and/or cure AMD and are reviewed herein.
机译:与年龄有关的黄斑变性(AMD)是西方世界失明的主要原因。随着人口的老龄化,预计AMD病例数将急剧增加,因此,解决这种使人衰弱的疾病成为欧洲联盟和全球社会经济未来的迫切需求。本文回顾了当前疗法的局限性以及AMD的社会经济影响。目前尚无AMD的治疗方法,甚至姑息治疗也很少见。治疗选择显示出多种副作用,成本高昂,仅治疗后果,而不是病理原因。因此,目前正在测试许多涉及以视网膜和虹膜色素上皮细胞以及干细胞为基础的细胞治疗方法。此外,用于设计和制造模仿Bruch膜的支架的组织工程策略非常多样化,并且正在研究中。两种替代疗法均旨在预防和/或治愈AMD,并且在本文中进行了综述。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号